Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Alterity Therapeutics Ltd (ATHE) ADR Each Representing 60 Shares

Sell:$1.02 Buy:$1.07 Change: $0.01 (0.99%)
NASDAQ:0.04%
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
Sell:$1.02
Buy:$1.07
Change: $0.01 (0.99%)
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
Sell:$1.02
Buy:$1.07
Change: $0.01 (0.99%)
Market closed |  Prices as at close on 14 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.

Contact details

Address:
L 3 460 Bourke St
MELBOURNE
3000
Australia
Telephone:
+61 (3) 93494906
Website:
pranabio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ATHE
ISIN:
US02155X1063
Market cap:
$13.67 million
Shares in issue:
536.98 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Australia
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Geoffrey Kempler
    Executive Chairman of the Board, Chief Executive Officer
  • Kathryn Andrews
    Chief Financial Officer
  • David Stamler
    Chief Medical Officer and Senior Vice President Clinical Development
  • Phillip Hains
    Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.